| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA534: Dupilumab for treating moderate to severe atopic dermatitis |
|
Medicine details |
|
| Medicine name | dupilumab (Dupixent®) |
| Formulation | 300 mg solution for injection |
| Reference number | 2457 |
| Indication | Treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy |
| Company | Sanofi-Aventis Ltd |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/09/2017 |
| NICE guidance | TA534: Dupilumab for treating moderate to severe atopic dermatitis |